Merck (MRK) Cash & Equivalents Growth (1y) (2010 - 2026)
Merck (MRK) Cash & Equivalents Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 14.42% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -30.58% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 74.25% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -38.20% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -40.42% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -13.23% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -57.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.46% |
| Mar 31, 2026 | -38.27% |
| Dec 31, 2025 | 9.99% |
| Sep 30, 2025 | 24.50% |
| Jun 30, 2025 | -29.17% |
| Mar 31, 2025 | 54.67% |
| Dec 31, 2024 | 93.57% |
| Sep 30, 2024 | 69.59% |
| Jun 30, 2024 | 99.72% |
| Mar 31, 2024 | -42.53% |
| Dec 31, 2023 | -46.11% |
| Sep 30, 2023 | -22.79% |
| Jun 30, 2023 | -41.50% |
| Mar 31, 2023 | 13.45% |
| Dec 31, 2022 | 56.79% |
| Sep 30, 2022 | 11.27% |
| Jun 30, 2022 | 12.83% |
| Mar 31, 2022 | 22.56% |
| Dec 31, 2021 | 0.57% |
| Sep 30, 2021 | 36.16% |